Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 7

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 7
---
 suffering from
AUD. After Phase I/IIa study initiation in Israel in March 2025, we initiated our Phase I/IIa clinical trial at the Johns Hopkins University
School of Medicine and Yale School of Medicine’s Department of Psychiatry in April 2025. In June 2025, we announced the addition
of Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel and Hadassah-University Medical Center in Jerusalem, Israel as additional
clinical sites for our ongoing Phase I/IIa clinical trial. In addition, also in June 2025, we announced that the first patient was enrolled
and dosed in our Phase I/IIa clinical trial at Yale School of Medicine’s Department of Psychiatry. In July 2025, we announced that
we received IRB approval from TASMC for our Phase I/IIa clinical trial , and in August 2025, we announced that we received IRB approval
from Hadassah-University Medical Center. In July 2025, we announced initiation of the TASMC clinical site.

The CM-CMND-001 clinical trial is designed to be
a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy
volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we will be required to conduct additional clinical
trials subject to securing additional financing.

<div align='center'>1</div>

About MEAI

MEAI is a synthetic molecule. Its mechanism of
action has been studied and published in the past in scientific papers. It was found to interact with the serotonergic receptors 5-HT1A
and 5-HT2B and the adrenergic receptors α2A, α2B and α2C receptors. The interaction with the 5HT2B receptor was determined
as non-agonist activity. Studies conducted in animals and humans have demonstrated the role of 5-HT1A receptors in alcohol-drinking behavior.
Several 5-HT1A receptor agonists have been tested in animal models to demonstrate the role of this receptor in alcohol dependence. These
preclinical studies suggest that 5-HT1A receptor agonists may play a role in reducing alcohol intake. In addition, evidence suggests that
α2-adrenergic receptor agonist signaling may play a role in mediating alcohol-drinking behavior in both rodents and humans.